Efficacy of Nintedanib Per os as a Treatment for Epistaxis in HHT Disease. A National, Randomized, Multicentre Phase II Study
Latest Information Update: 08 Aug 2023
At a glance
- Drugs Nintedanib (Primary)
- Indications Epistaxis
- Focus Therapeutic Use
- Acronyms EPICURE
Most Recent Events
- 03 Aug 2023 Status changed from recruiting to completed.
- 30 Mar 2023 This trial has been completed (End Date: 24 Mar 2023), according to European Clinical Trials Database record.
- 02 Oct 2020 Planned End Date changed from 1 Oct 2022 to 1 Dec 2022.